With All Amino Acids In L-form (c07k-10a) Patents (Class 930/DIG821)
-
Patent number: 5643876Abstract: A class of broad spectrum bioactive polypeptides termed "Magainin" have been described. These peptides have a molecular weight of about 2500 or less, are highly water soluble, amphiphilic and non-hemolytic.Type: GrantFiled: October 19, 1992Date of Patent: July 1, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Michael A. Zasloff
-
Patent number: 5446130Abstract: Peptide derivatives of the following general formula (I): ##STR1## wherein AAA is deletion or Ser, BBB is deletion or Glu, CCC is deletion, Ile, Phe, Leu, cyclohexylalanine, D-alle or Lys substituted at the .epsilon.-position by C.sub.6 --C.sub.18 alkylcarbonyl group, DDD is Gly or Gln, EEE is Leu, Nle or Phe, FFF is Met, Leu or Nle, GGG is Ala, Ser Leu, Asn, Asp or Gln, HHH is Leu, Glu or Lys, III is His, Lys or Arg, JJJ is His, Lys or Arg, Xaa is Ala modified at the carboxy terminal with an amino group, provided that CCC and DDD may independently be modified at the amino terminal by C.sub.2 --C.sub.Type: GrantFiled: September 13, 1994Date of Patent: August 29, 1995Assignee: Mitsubishi Kasei CorporationInventors: Tatsuhiko Kanmera, Akihisa Mori, Yoshihide Nakao, Toshihiko Minegishi
-
Patent number: 5397772Abstract: Disclosed are proteins derived from the sand fly Lutzomyia longipalpis capable of inducing vasodilation in mammals, and data characterizing the proteins and nucleic acid encoding the proteins. Also disclosed is a method for temporarily inactivating the immune system in a mammal comprising administering to the mammal the Lutzomyia protein, CGRP, calcitonin, or active immune suppressing analogs thereof.Type: GrantFiled: October 15, 1993Date of Patent: March 14, 1995Assignee: The President and Fellows of Harvard CollegeInventors: Jose M. C. Ribeiro, Ethan A. Lerner, Heinz G. Remold, Richard G. Titus
-
Patent number: 5372933Abstract: Receptor-induced binding sites (RIBS) expressed in a ligand when that ligand is bound in a complex with a receptor are disclosed, as are polypeptides that correspond in amino acid residue sequence with a RIBS expressed by a receptor-ligand complex. Particularly-preferred polypeptides correspond to a RIBS amino acid sequence of the gamma chain of human fibrinogen. Monoclonal antibodies that immunoreact with a RIBS but do not substantially immunoreact with either the ligand or the receptor when free in solution are also disclosed, as are hybridomas secreting those antibodies, and methods of making and using such antibodies.Type: GrantFiled: February 12, 1991Date of Patent: December 13, 1994Assignee: The Scripps Research InstituteInventors: Concepcion Zamarron, Edward F. Plow, Mark H. Ginsberg
-
Patent number: 5317010Abstract: Analogues of bovine and human parathyroid hormone, wherein twenty-fifth, twenty-six and twenty-seventh positions of the natural hormone, Arg-Lys-Lys- each have been substituted with Ala, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val have been found to retain bone cell effect with minimal effects on blood pressure and smooth muscle, including cardiac muscle. It has further been found that this effect can be obtained by using a synthetic PTH containing only the first 34 amino acids of PTH, with substitution at the twenty-fifth, twenty-sixth and twenty-seventh amino acids as described. These analogues of PTH also are effective in the treatment of osteoporosis and other bone diseases.Type: GrantFiled: October 10, 1991Date of Patent: May 31, 1994Assignee: Peter K. T. PangInventors: Peter K. T. Pang, Jie Shan
-
Patent number: 5239059Abstract: A biologically active peptide which includes the following structure:R.sub.1 --R.sub.1 --R.sub.1 --R.sub.3 --R.sub.5 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.1 R.sub.3 --R.sub.1 --R.sub.4 --R.sub.1 --R.sub.3 --R.sub.4 --R.sub.1 --R.sub.1.R.sub.1 is a hydrophobic amino acid, R.sub.2 is a basic hydrophilic amino acid, and R.sub.3 is a neutral hydrophilic amino acid, R.sub.4 is a hydrophobic or basic hydrophilic amino acid, and R.sub.5 is a hydrophobic, basic hydrophilic, or neutral hydrophilic amino acid.Examples of such peptides include the following:(SEQ ID NO:1)--NH.sub.2 ;(SEQ ID NO:2)--NH.sub.2 ;(SEQ ID NO:3)--NH.sub.2 ;(SEQ ID NO:4)--NH.sub.2 ;(SEQ ID NO:5)--NH.sub.2 ;(SEQ ID NO:6)--NH.sub.2 ;(SEQ ID NO:7)--NH.sub.2 ; and(SEQ ID NO:8).The peptides may be employed in pharmaceutical compositions.Type: GrantFiled: May 10, 1991Date of Patent: August 24, 1993Assignee: The Children's Hospital of PhiladelphiaInventors: Michael Zasloff, U. Prasad Kari, W. Lee Maloy
-
Patent number: 5234907Abstract: Vasoactive intestinal compound analogs containing substitutions of appropriately selected amino acids at specific positions of the VIP molecule.Type: GrantFiled: April 24, 1991Date of Patent: August 10, 1993Assignee: Hoffmann-La Roche Inc.Inventor: David R. Bolin
-
Patent number: 5229489Abstract: Peptide derivatives of the following general formula (I): Seq. ID Nos. 1-6. ##STR1## wherein AAA is deletion or Ser, BBB is deletion or Glu, CCC is deletion, Ile, Phe, Leu, cyclohexylalanine, D-alle or Lys substituted at the .epsilon.-position by C.sub.6 -C.sub.18 alkylcarbonyl group, DDD is Gly or Gln, EEE is Leu, Nle or Phe, FFF is Met, Leu or Nle, GGG is Ala, Ser, Leu, Asn, Asp or Gln, HHH is Leu, Glu or Lys, III is His, Lys or Arg, JJJ is His, Lys or Arg, Xaa is Ala modified at the carboxy terminal with an amino group, provided that CCC and DDD may independently be modified at the amino terminal by C.sub.2 -C.sub.Type: GrantFiled: April 12, 1991Date of Patent: July 20, 1993Assignee: Mitsubishi Kasei CorporationInventors: Tatsuhiko Kanmera, Akihisa Mori, Yoshihide Nakao, Toshihiko Minegishi
-
Patent number: 5217953Abstract: The present invention relates to a peptide encoding an antagonist of VIP. The invention also relates to a method of using said peptide to antagonize VIP function. The invention further relates to a pharmaceutical composition.Type: GrantFiled: November 30, 1990Date of Patent: June 8, 1993Assignee: The United States of America as represented by the Secretary of the Department of Health & Human ServicesInventors: Illana Gozes, Douglas E. Brenneman, Mati M. Fridkin, Terry Moody
-
Patent number: 5177189Abstract: The present invention contemplates a multimeric polypeptide capable of mimicking the ability of Apo E in regulating lymphocyte proliferation and ovarian androgen synthesis.Type: GrantFiled: August 18, 1989Date of Patent: January 5, 1993Assignee: The Scripps Research InstituteInventors: Cheryl A. Dyer, Linda K. Curtiss, Richard Smith
-
Patent number: 5175251Abstract: Human laminin B.sub.1 peptides have been produced. The invention provides novel peptides which contain substantial amino acid sequence similarity to amino acids 897 to 936 in the human sequence. These peptides have been found to have enhanced antimetastatic activity.Type: GrantFiled: October 29, 1991Date of Patent: December 29, 1992Assignee: SRI InternationalInventors: Paul H. Johnson, Jerome B. Lazar, David G. Streeter
-
Patent number: 5141924Abstract: Vasoactive intestinal peptide analogs containing substitutions of appropriately selected amino acids at specific positions of the VIP molecule.Type: GrantFiled: June 30, 1989Date of Patent: August 25, 1992Assignee: Hoffmann-La Roche, Inc.Inventor: David R. Bolin
-
Patent number: 5142025Abstract: Novel recombinant HTLV-III fusion proteins denoted R10, PB1, 590, KH1, and the HIV portion of each of these proteins are useful in the diagnosis, prophylaxis or therapy of AIDS. Protein R10 is a 95 kD fusion protein; protein PB1 is a 26 kD fusion protein; protein 590 is an 86 kD fusion protein; and protein KH1 is a 70 kD fusion protein. These proteins are considered to be especially useful to prepare vaccines for the HTLV-III virus.Type: GrantFiled: September 24, 1990Date of Patent: August 25, 1992Assignee: Repligen CorporationInventors: Scott D. Putney, Debra Lynn, Kashayar Javaherian, William T. Mueller, John Farley
-
Patent number: 5128242Abstract: The present invention relates to peptides having adenylate cyclase stimulating activity. The peptides all have at least the sequence His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr- Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-.Type: GrantFiled: June 19, 1989Date of Patent: July 7, 1992Assignee: The Administrators of the Tulane Educational FundInventors: Akira Arimura, Atsuro Miyata
-
Patent number: 5114843Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide analogues is exemplified by an internal region of the N-terminus of humoral hypercalcemic factor hHCF, and truncations thereof: hHCF(14-34)NH.sub.2, hHCF(13-34)NH.sub.2, hHCF(12-34)NH.sub.2, hHCF(11-23)NH.sub.2, hHCF(10-34)NH.sub.2, hHCF(9-34)NH.sub.2, hHCF(8-34)NH.sub.2 and various amino acid substitutions.Type: GrantFiled: February 25, 1991Date of Patent: May 19, 1992Assignee: Merck & Co., Inc.Inventors: Michael Rosenblatt, Roberta L. McKee, Michael P. Caulfield, Ruth F. Nutt
-
Patent number: 5075211Abstract: Novel peptides are provided having substantially the same sequence as immunologically significant fragments of AIDS-related viruses. The polypeptides can be used as reagents in the determination of exposure of a human host to the virus. Of particular interest is the use of polypeptides in screening blood products.Type: GrantFiled: November 14, 1986Date of Patent: December 24, 1991Assignee: Genetic Systems CorporationInventors: Wesley L. Cosand, Linda J. Harris, Raymond L. Houghton
-
Patent number: 5051496Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.Type: GrantFiled: January 16, 1987Date of Patent: September 24, 1991Assignee: Institut PasteurInventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader